Townsend Letter Alternative Medicine Magazine



  FREE e-Edition


 EDTA Chelation Therapy


 E-mail List

From the Townsend Letter
April 2014

Nonalcoholic Fatty Liver Disease
in Chronic Hepatitis C

by Lyn Patrick, ND
Search this site

Page 1, 2

1.  Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131.
2.  Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis. 2006;10:697–715.
3.  Colvin HM, Mitchell AE, eds. Hepatitis and Liver Cancer: a National Strategy for Prevention and Control of Hepatitis B and C. Washington, D.C.: National Academies Press; 2009:237.
4.  Patel A, Harrison S. Hepatitis C virus infection and nonalcoholic steatohepatitis. Gastroenterol Hepatol. 2012;8(5):305–312.
5.  Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636–1642.
6.  Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer. 2003;97:3036–3043.
7.  Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavarin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38:75–85.
8.  Shaheen M, Echeverry D, Oblad MG, et al. Hepatitis C, metabolic syndrome, and inflammatory markers: results from the third national health and nutrition examination survey [NHANES III]. Diabetes Res Clin Pract. 2007;75:320–326.
9.  Chalasani N, Younossi Z, Lavine J, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guidelines by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. Epub 2012. 110.
10.  Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus among persons born during 1945–1965. MMWR. August 17, 2012;81(RRO4):1–18.
11.  Ghany MG, Strader D, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update.Hepatology. 2009:49(4):1335–1374.
12.  Castera L, Hezode C, Roudot-Thoraval F, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut. 2004;53:420–424.
13.  Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepatitis. 2006;13:73–80.
14.  Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology. 2003;125:1695–1704.
15.  McCaughan GW, George J. Fibrosis progression in chronic hepatitis C virus infection. Gut. 2004;53:318–321.
16.  Lonardo A, Adinolfi LE, Paola L. Mechanisms of hepatitis C virus-induced liver disease. Hot Topics in Viral Hepatitis. 2009;14:23–29.
17.  Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43(8):617–649.
18.  Lonardo A, Ballestri S, Adinolfi LE, et al. Hepatitis C virus- infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. Can J Gastroenterol. 2009;23(4):273–278.
19.  Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34:738–744.
20.  Finelli C, Tarantino G. Is there any consensus as to what diet or lifestyle approach Is the right one for NAFLD patients? J Gastrointestin Liver Dis. September 2012;21(3):293–302
21.  Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut.2002;51:89–94.
22.  Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004 Mar; 53(3):413–419.
23. Tishinsky JM, Dyck DJ, Robinson LE. Lifestyle factors increasing adiponectin synthesis and secretion. Vitam Horm. 2012;90:1–30.
24.  Kim S, Kwon H, Park JH, et al. A low level of serum testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterology. 2012;12:69.
25.  Kraus MR, Schafer A, Bentink T, et al. Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: interferon-induced functional androgen deficiency or depression? J Endocrinol. 2005;185;345–352.
26.  Nguyen HV, Mollison LC, Taylor T, et al. Chronic hepatitis C infection and sex hormone levels: effect of disease severity and recombinant interferon-α therapy. Int Med J. 2006;36:362–366.
27.  Jain SK, Pemberton PW, Smith A, et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol. 2002;36(6):805–811.
28.  Choi J , Ou JH. Mechanisms of liver injury III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006;290:847–851.
29.  Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of D-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology. 1997;113:1069–1073.
30.  Lai IK, Dhakal K, Gadupudi GS, Li M, et al. N-acetylcysteine (NAC) diminishes the severity of PCB 126-induced fatty liver in male rodents. Toxicology. 2012 Dec 8;302(1):25–33.
31.  Mukjerjee S. Betaine and nonalcoholic steatohepatitis: Back to the future? J Gastroenterol. 2011 August 28;17(32):3663–3664.
32.  Himoto T, Yoneuyama H, Deguch A, et al. Insulin resistance derived from zinc deficiency in non-diabetic patients with chronic hepatitis C. Exp Therapeut Med. 2010;1:707–711.
33.  Himoto T, Hosomi N, Nakai S, et al. Effect of zinc administration in patients with hepatitis C virus-related chronic liver disease. Scand J Gastroenterol. 2007;42:1078–1087.
34.  Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci. 2010;55:2624–2628.
35.  Milazzo L, Mazzali C, Bestetti G, et al. Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population. Curr HIV Res. 2011;9:186–193.
36.  Sardar S, Chakraborty A, Chatterjee M. Comparative effectiveness of vitamin D3 and dietary vitamin E on peroxidation of lipids and enzymes of the hepatic antioxidant system in Sprague-Dawley rats. Int J Vitam Nutr Res. 1996;66:39–45.
37.  Bitetto D, Fabris C, Fornasiere E, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Tranpl Int. 2011;24:43–50.

Lyn Patrick, NDLyn Patrick, ND, graduated from Bastyr University in 1985 and has practiced in Arizona and Colorado for the last 27 years as a primary care provider specializing in environmental medicine and chronic hepatitis C. Her expertise in chronic hepatitis C originated with her work in an HIV practice and matured in her collaboration with the Hepatitis C Ambassadors as part of the Hepatitis C Brainstorming Team ( This international team of doctors, epidemiologists, acupuncturists, NDs, and advocates has worked together to provide an integrative health model for the treatment of chronic hepatitis C. The group has written a free online book for patients that spans the spectrum of diagnosis and care ( Dr. Patrick also lectures internationally on fatty liver disease and chronic hepatitis C to health-care providers and is currently coteaching a Hepatitis C Certification Program with Misha Cohen, OMD, through Progressive Medical Education (

Page 1, 2

Consult your doctor before using any of the treatments found within this site.

Subscriptions are available for Townsend Letter, the Examiner of Alternative Medicine
magazine, which is published 10 times each year. Search our pre-2001 archives for further information. Older issues of the printed magazine are also indexed for your convenience.
1983-2001 indices ; recent indices. Once you find the magazines you'd like to order, please
use our convenient form, e-mail, or call 360.385.6021.


Fax: 360.385.0699

Who are we? | New articles | Featured topics | e-Edition |
Tables of contents
| Subscriptions | Contact us | Links | Classifieds | Advertise |
Alternative Medicine Conference Calendar | Search site | Archives |
EDTA Chelation Therapy | Home

© 1983-2014 Townsend Letter
All rights reserved.
Website by Sandy Hershelman Designs